思创医惠科技股份有限公司第六届董事会提名委员会 关于第六届董事会独立董事候选人任职资格的审查意见 思创医惠科技股份有限公司（以下简称"公司"）第六届董事会提名委员会 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《上市公司独立 董事管理办法》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市 公司规范运作》（以下简称"《规范运作》"）等法律法规、规范性文件和《公 司章程》的相关规定，对公司第六届董事会独立董事候选人何毅琦先生的任职资 格进行了审查，并发表审查意见如下： 一、独立董事候选人何毅琦先生符合《上市公司独立董事管理办法》等法律 法规规定的独立董事任职资格和独立性要求，具备履行独立董事职责的专业知识、 工作经验和职业素养，不存在《公司法》《规范运作》等法律法规和《公司章程》 中规定的不得担任董事、独立董事的情形，不存在被中国证监会确定为市场禁入 者且尚未解除的情况，不存在重大失信等不良记录，也未曾受到中国证监会和证 券交易所的处罚和惩戒，具备担任上市公司独立董事的履职能力。 二、独立董事候选人何毅琦先生尚未取得独立董事资格证书，其已书面承诺 参加最近一次独立董事培训并取得深圳证券交易 ...

Investment Rating - The report maintains an "Overweight" rating for the computer industry, expecting the industry index to outperform the market index by more than 10% in the next six months [1]. Core Insights - The current external environment is causing disturbances, increasing policy risks and uncertainties, which highlight the urgency for technological self-reliance in China. This situation is expected to accelerate the domestic substitution process, presenting new development opportunities for the domestic software and industrial software sectors [2][27]. - The report suggests focusing on companies with competitive advantages in foundational hardware, foundational software (databases, operating systems, middleware), and application software within the domestic software sector. In the industrial software sector, attention should be directed towards companies excelling in product design, production control, and operational management [2][27]. Summary by Sections 1. Industry Performance Review - The Shenwan computer sector experienced a cumulative decline of 4.21% from October 9 to October 16, 2025, underperforming the CSI 300 index by 3.73 percentage points, ranking 28th among 31 Shenwan primary industries. Year-to-date, the sector has risen by 22.64%, outperforming the CSI 300 index by 5.27 percentage points [9][19]. 2. Valuation Situation - As of October 16, 2025, the Shenwan computer sector's PE TTM (excluding negative values) stands at 57.38 times, placing it in the 91.01 percentile for the past five years and the 84.33 percentile for the past ten years [19][21]. 3. Industry News - Key developments include the U.S. imposing export controls on critical software to China, a 12.6% year-on-year increase in China's software business revenue from January to August 2025, and strategic collaborations in AI technology between OpenAI and Broadcom [20][22]. 4. Company Announcements - Notable announcements include acquisitions and performance forecasts from various companies, indicating growth in sectors such as industrial software and smart logistics [23][24]. 5. Weekly Perspective - The report emphasizes the urgency for technological self-reliance in China, suggesting that the domestic software and industrial software sectors may see new growth opportunities due to increased policy risks and uncertainties [27]. 6. Recommended Companies - The report lists several companies to watch, including: - GuoDianYunTong (002152.SZ) for its stable growth in financial technology - Digital China (000034.SZ) as a core partner in the "Kunpeng + Ascend" industry chain - Inspur Information (000977.SZ) for its leadership in AI server markets [28].

Core Insights - The healthcare insurance information system plays a crucial role in managing medical insurance, improving service efficiency, and supporting fund supervision and quality assessment [1][3][8] - The market size of China's healthcare insurance information system is projected to reach 4.8 billion yuan in 2024, reflecting a year-on-year growth of 6.4% [1][8][9] Industry Overview - The healthcare insurance information system is a computer system designed to manage medical insurance operations, including participant management, cost settlement, fund supervision, and data sharing [3][4] - The industry has evolved through four stages, from standalone systems to the current core platform construction phase, driven by technological advancements [4][5] Market Development - The market for healthcare insurance information systems has shown an upward trend, despite delays in construction and acceptance due to the pandemic in 2022 [1][8] - The number of participants in basic medical insurance in China is expected to rise, providing a substantial data foundation for healthcare information systems [7][8] Competitive Landscape - The competition in the healthcare insurance information system industry is intensifying, with the top five companies holding a market share of 36.3% in 2024 [9] - Neusoft Corporation maintains a significant market share of 15.1%, leveraging its early market entry and extensive service capabilities [9][10] Future Trends - The future of healthcare insurance information systems will focus on data sharing, interoperability, and the use of advanced technologies like big data and artificial intelligence to enhance service personalization [11] - Data security and privacy protection will become critical areas of development for the industry [11]

Group 1 - Dingjide's subsidiary has successfully launched the industrial production of POE materials, achieving stable production of qualified products [1] - Xinhua Insurance reported a 19% year-on-year increase in original insurance premium income for the first three quarters, totaling 172.705 billion yuan [1] - Chunfeng Power achieved a 30.89% year-on-year increase in net profit for the first three quarters, with total revenue reaching 14.15 billion yuan [1][2] Group 2 - Guangsheng Nonferrous expects a net profit of 100 million to 130 million yuan for the first three quarters, marking a turnaround from losses [1] - Aobi Zhongguang anticipates a net profit of approximately 108 million yuan for the first three quarters, with revenue growth of 103.5% [1] - Guobang Pharmaceutical reported a 15.78% year-on-year increase in net profit for the first three quarters, totaling 6.7 billion yuan [1] Group 3 - Zhujiang Co. manages 428 projects with a signed construction area of approximately 50.9853 million square meters as of September 2025 [1] - Kecuan Technology has terminated its application for issuing convertible bonds, considering its development plan and actual situation [1] - Guoxin Securities has received approval to register 15 billion yuan in short-term corporate bonds [1] Group 4 - Aihua Pharmaceutical's clinical trial for a pediatric cough syrup has been approved by the National Medical Products Administration [1] - Xinjiang Jiaojian signed new construction contracts worth 1.413 billion yuan in the third quarter [1] - Sichuan Shuangma's subsidiary has received approval for the listing of a raw material drug used in treating various diseases [1] Group 5 - Gansu Energy's 1,000 MW coal-fired unit has officially commenced commercial operation [1] - Zhejiang Energy reported a 4.68% year-on-year increase in power generation for the first three quarters, totaling 135.234 billion kWh [1] - Tiandi Source's contract sales amount for the first nine months decreased by 16.18% to 3.085 billion yuan [1] Group 6 - Biological Shares' subsidiary has obtained a new veterinary drug registration certificate for a vaccine [1] - Jintong Co. reported a 4.03% year-on-year increase in net profit for the first three quarters, totaling 2.283 billion yuan [1] - Rihua Technology plans to invest 800 million yuan in a new project for industrial ray detection equipment [1] Group 7 - Zhongtian Technology has won multiple marine project bids totaling approximately 1.788 billion yuan [1] - Qingsong Co. has completed the disposal of a 148-acre industrial park project, transferring it for 163 million yuan [1] - Tongyuan Petroleum has successfully bid for a $126 million oil and gas service project in Algeria [1] Group 8 - Hengmingda's chairman proposed a share buyback plan of 200 million to 400 million yuan [1] - Deyi Cultural plans to reduce its holdings by up to 1% of the company's shares [1] - Feirongda's major shareholder plans to reduce its holdings by up to 2.36% of the company's shares [1] Group 9 - Mankun Technology plans to issue convertible bonds to raise no more than 760 million yuan for high-end PCB production and digital upgrades [1] - Sanlian Forging's shareholder plans to reduce its holdings by up to 3% of the company's shares [1] - Huagong Technology intends to jointly establish a venture capital fund with a target size of 500 million yuan [1] Group 10 - Shida Shenghua expects a net loss of 49 million to 75 million yuan for the first three quarters [1] - Huichuangda's major shareholder plans to reduce its holdings by up to 0.65% of the company's shares [1] - Yuxin Electronics reported a 60.21% year-on-year increase in net profit for the first three quarters, totaling 73.3941 million yuan [1] Group 11 - Yiwei Communication expects a 50% to 55% decline in net profit for the first three quarters [1] - Lio Co. plans to reduce its repurchased shares by up to 135 million shares [1] - Sichuan Shuangma's subsidiary has received approval for a new drug registration [1]

Core Insights - The internet healthcare sector experienced a decline of 0.59% on October 16, with Rongke Technology leading the drop [1] - The Shanghai Composite Index closed at 3916.23, up 0.1%, while the Shenzhen Component Index closed at 13086.41, down 0.25% [1] Stock Performance - Notable gainers in the internet healthcare sector included: - Wanma Technology (300698) with a closing price of 50.09, up 10.94% and a trading volume of 237,000 shares, totaling 1.177 billion yuan [1] - Fengzhou Ziling (002424) at 5.95, up 9.98% with a volume of 482,600 shares, totaling 281 million yuan [1] - New Mileage (002219) at 2.45, up 9.87% with a volume of 3.4548 million shares, totaling 833 million yuan [1] - Decliners included: - Moke Technology (300290) at 22.16, down 8.54% with a volume of 435,700 shares, totaling 976 million yuan [2] - Zhongyuan Shares (300018) at 10.45, down 6.28% with a volume of 472,200 shares, totaling 500 million yuan [2] Capital Flow - The internet healthcare sector saw a net outflow of 702 million yuan from institutional investors, while retail investors contributed a net inflow of 343 million yuan [2][3] - Key stocks with significant capital flow included: - New Mileage (002219) with a net inflow of 1.59 billion yuan from institutional investors, but a net outflow from retail investors [3] - Wanma Technology (300698) with a net inflow of 146 million yuan from institutional investors [3]

Core Insights - On October 16, 2023, 13 companies released their Q3 2025 financial reports, with 12 reporting year-on-year profit growth and 10 showing revenue growth [1] - Guanghua Technology reported the highest profit growth at 1233.70%, indicating a significant performance increase [1] Summary by Category Profit Performance - Guanghua Technology: Net profit of 90.39 million yuan, up 1233.70% YoY [1] - Yuxin Electronics: Net profit of 73.39 million yuan, up 60.21% YoY [1] - Xinzhi Group: Net profit of 121.51 million yuan, up 39.49% YoY [1] - Haiguang Information: Net profit of 196.14 million yuan, up 28.56% YoY [1] - Other companies with profit growth include Zongyi Co., Jiuzhou Pharmaceutical, and Beijing Lier [1] Revenue Performance - Guanghua Technology: Revenue of 2.04 billion yuan, up 11.50% YoY [1] - Yuxin Electronics: Revenue of 572.13 million yuan, up 40.97% YoY [1] - Haiguang Information: Revenue of 948.99 million yuan, up 54.65% YoY [1] - Other companies with revenue growth include Zongyi Co., Jiuzhou Pharmaceutical, and Beijing Lier [1] Companies with Declining Performance - Qin Chuan Wulian: Reported a net loss of 69.90 million yuan, down 66.72% YoY [1] - Xue Rong Biological: Net loss of 62.35 million yuan, up 61.94% YoY [1] - Other companies with declining revenue include Xue Rong Biological and Qin Chuan Wulian [1]

Core Insights - As of October 16, 2023, 25 companies have released their Q3 2025 financial reports, with 23 reporting year-on-year profit growth and 18 showing revenue growth [1] - The company with the highest profit growth is Guanghua Technology, with a staggering increase of 1233.70% [1] Financial Performance Summary - **Profit Growth**: 23 companies reported profit growth, while 2 experienced declines [1] - **Revenue Growth**: 18 companies reported revenue growth, with 7 showing declines [1] - **Notable Performers**: Guanghua Technology leads with a profit of 90.39 million yuan and revenue of 2.04 billion yuan, marking a profit growth of 1233.70% and revenue growth of 11.50% [1] - **Other High Performers**: - Daoshi Technology: Profit of 415.44 million yuan, profit growth of 182.45%, revenue of 600.09 million yuan, revenue decline of 1.79% [1] - Sichuang Medical: Profit of -0.48 million yuan, profit growth of 98.32%, revenue of 60.38 million yuan, revenue growth of 6.95% [1] - Xiaogoods City: Profit of 3.46 billion yuan, profit growth of 48.45%, revenue of 13.06 billion yuan, revenue growth of 23.07% [1] Declining Performers - **Profit Declines**: Qin Chuan Technology reported a profit decline of 66.72% with a loss of 6.99 million yuan and revenue decline of 16.24% [2] - **Other Decliners**: - High Energy Environment: Profit growth of 15.18% with revenue decline of 11.28% [2] - Qifeng New Materials: Profit decline of 3.82% with revenue decline of 0.83% [2]

单看第三季度，思创医惠实现的营业收入约为5879.51万元，同比下降64.93%；对应实现的归属净利润 约为4706.93万元，同比增长177.42%。 北京商报讯（记者 丁宁）10月15日晚间，思创医惠（300078）发布2025年三季度报告显示，公司前三 季度实现的营业收入约为6.04亿元，同比增长6.95%；对应实现的归属净利润约为-476.22万元，同比增 长98.32%。 ...

Core Insights - The company reported a revenue of 604 million yuan for the first three quarters of 2025, representing a year-on-year growth of 6.95% [1] - The net loss attributable to shareholders of the listed company was 4.76 million yuan [1] - The net loss attributable to shareholders after deducting non-recurring gains and losses was 158 million yuan [1]

Core Insights - The company, 思创医惠, reported a significant decline in revenue for Q3 2025, with a total revenue of 58.79 million yuan, representing a year-on-year decrease of 64.93% [1] - The company achieved a net profit attributable to shareholders of 47.07 million yuan in Q3, marking a turnaround from previous losses [1] - For the first three quarters of 2025, the company recorded a net loss attributable to shareholders of 4.76 million yuan [1]